Insights from ESMO24 Day 1

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.

ESMO shared some insights from the conference on social media.

ESMO and WHO: Tackling Cancer Worldwide

Eye-opening ESMO24 session, Saturday 14 September 10:15hrs, Zaragoza Auditorium. Don’t miss out!

Multi-gene ctDNA profiling guides management

ESMO24: Multi-gene ctDNA profiling guides management by effectively matching patients with advanced cancer to Targeted Therapies.

FRESH programme established to facilitate access to Liquid Biopsy for Precision Oncology across France.

Predictive biomarkers are crucial

ESMO24: Promising but inconclusive results reported for novel antiangiogenic agents in NETs. Data warrant further exploration in Clinical Trials. Predictive biomarkers are crucial.

ADRIATIC study with durvalumab immunotherapy

ESMO24: Subgroup analyses from the ADRIATIC study with durvalumab immunotherapy in limited-stage small cell lung cancer support previous practice-changing findings.

Opening Ceremony at ESMO24

The Opening Ceremony marks the official start of ESMO24. Over the next five days, attendees will hear from inspiring speakers, delve into new research, and connect with peers who share their same passion for finding improved ways to care for patients with cancer.

ADCs in metastatic breast cancer

New positive findings from research with ADCs offer hope for patients with advanced or metastatic Breast Cancer, including those with brain metastases, and support their use in wider patient populations .

For more updates on ESMO24, visit oncodaily.com